We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood-Based Test Allows for Minimally Invasive Detection of IDH1.R132H-Mutant Gliomas

By LabMedica International staff writers
Posted on 04 Sep 2024

Glioma is the most prevalent type of central nervous system cancer in adults. More...

It is classified based on molecular alterations, notably the IDH1.R132H mutation, which helps in grouping lesions into different prognostic categories. Traditionally, gliomas are diagnosed through neuroimaging and subsequent tissue biopsies, which include surgical biopsies or resections. These methods, while standard, carry procedural risks and may not capture the full complexity and variability of the tumor. Moreover, knowing the IDH mutation status before surgery can guide the surgical approach. Researchers have now developed a blood test that detects tumor-derived extracellular RNA from just 2ml of blood, providing a minimally invasive diagnostic option.

The blood-based test, mt-IDHIdx, was developed by researchers at Massachusetts General Hospital (Boston, MA, USA) and validated across the study population (n=133) involving 133 individuals—80 with IDH1.R132H mutant gliomas, 44 with IDH1 wild-type gliomas, and nine healthy controls. The results from plasma testing published in Nature Communications show an overall sensitivity of 75.0% (95% CI: 64.1%–84.0%) and a specificity of 88.7% (95% CI: 77.0%–95.7%), with a positive predictive value of 90.9% and a negative predictive value of 70.1%, when compared to the traditional tissue-based methods. This blood-based testing not only serves diagnostic purposes but is also useful for ongoing monitoring and surveillance of the disease.

The workflow of this testing method is optimized, allowing for the analysis of tumor tissue and plasma samples to be completed in less than four hours from collection. With the ability to detect the IDH1 mutation from a blood sample, this approach enables non-invasive diagnosis and the monitoring of disease progression, treatment response, or recurrence. This breakthrough comes at a pivotal time as the FDA recently approved a new therapy, vorasidenib, targeting this mutation. Once the blood test is approved, it could significantly aid in selecting appropriate treatments and in managing patient care over time.

Related Links:
Massachusetts General Hospital


New
Gold Member
Hybrid Pipette
SWITCH
Portable Electronic Pipette
Mini 96
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.